O uso de Canabinóides no tratamento de epilepsia: uma análise por revisão bibliográfica

Abstract

Approximately 3% of the world population live with epilepsy, a neurological disorder that can be cured with surgery only in few cases, in other and, only remains symptom control through the use of antiepileptic drugs. However, 30% of these patients remain resistant to pharmacotherapy. The cannabinoids appears as a promising target for development of a new drugs focus on the seizures control and the results form this disease, since this compounds act directly on the endocannabinoid system. Objective: This article aims to search literature references that evaluate the anticonvulsivant effect of cannabinoids compounds in rats. Methods: Literature review in the following databases: Scopus, Medline, Bireme, Science Direct, SciELO and Web of Science. The following parameters were analyzed: type of cannabinoid used, dose and time of administration, analysis of seizures and the respective results and if the cannabinoids are legalized in the country where the study was developed. Results: It is located 525 results, and to analyze titles, in the end, only 7 articles were acepted for this stuoy. The most common cannabinoid was cannabidivarin (CBDV) and the country with largest number of articles was the United Kingdom. The parameters evaluated in the articles were frequency, latency and severity of seizures and all cannabinoides compounds presented benefic effects. Conclusion: Cannabinoids appear as promising alternative for treatment of epileptic seizures. However, it is necessary further studies about the cannabinoid action in the central nervous system, since there are very limited studies due to no legalization of Cannabis sativa in most countries.